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Abstract
Background: This study sought to map the Insomnia Severity Index (ISI) and symptom variables onto the EQ-5D.
Methods: A cross-sectional survey was conducted among adult US residents with self-reported sleep problems.
Respondents provided demographic, comorbidity, and sleep-related information and had completed the ISI and
the EQ-5D profile. Respondents were classified into ISI categories indicating no, threshold, moderate, or severe
insomnia. Generalized linear models (GLM) were used to map the ISI’s 7 items (Model I), summary scores (Model II),
clinical categories (Model III), and insomnia symptoms (Model IV), onto the EQ-5D. We used 50% of the sample for
estimation and 50% for prediction. Prediction accuracy was assessed by mean squared errors (MSEs) and mean
absolute errors (MAEs).
Results: Mean (standard deviation) sleep duration for respondents (N = 2,842) was 7.8 (1.9) hours, and mean ISI
score was 14.1 (4.8). Mean predicted EQ-5D utility was 0.765 (0.08) from Models I-III, which overlapped with
observed utilities 0.765 (0.18). Predicted utility using insomnia symptoms was higher (0.771(0.07)). Based on Model I,
predicted utilities increased linearly with improving ISI (0.493 if ISI = 28 vs. 1.00 if ISI = 0, p < 0.01). From Model II,
each unit decrease in ISI summary score was associated with a 0.022 (p < 0.001) increase in utility. Predicted
utilities were 0.868, 0.809, 0.722, and 0.579, respectively, for the 4 clinical categories, suggesting that lower utility
was related to greater insomnia severity. The symptom model (Model IV) indicated a concave sleep-duration
function of the EQ-5D; thus, utilities diminished after an optimal amount of sleep. The MSEs/MAEs were
substantially lower when predicting EQ-5D > 0.40, and results were comparable in all models.
Conclusions: Findings suggest that mapping relationships between the EQ-5D and insomnia measures could be
established. These relationships may be used to estimate insomnia-related treatment effects on health state utilities.
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Introduction
Insomnia is a disorder broadly defined by difficulty with
sleeping. It may be characterized by 1) primary insom-
nia, without underlying medical cause; 2) secondary
insomnia, with presence of an underlying medical cause;
3) acute insomnia, symptoms with a short duration or;
4) chronic insomnia, symptoms with a long duration
[1,2]. Patients with insomnia commonly complain of
difficulties initiating/maintaining sleep, early awakening,
and non-restorative or poor quality sleep [3].
The prevalence of insomnia in the adult population
ranges from 10% to 30% [1,4-6]. Insomnia is associated
with substantial burden to patient and society. Persistent
or prolonged sleeping problems have been associated
with worsened health outcomes including reduced pro-
ductivity or physical/social functioning, increased risk of
occupational accidents or major depression/anxiety dis-
orders, poorer health-related quality-of-life (HRQoL)
and, increased health care costs [7-13]. Meanwhile,
sleep-related conditions have often been under-diag-
nosed and under-treated [14].
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specific instruments have been used to identify and
describe the condition. These instruments include, but
are not limited to, the 36-Item Short-Form Health Sur-
vey [15], the Leeds Sleep Evaluation Questionnaire [16],
the Medical Outcomes Study Sleep Scale 12 [17], the
Epworth Sleepiness Scale [18,19], the Functional Out-
comes of Sleep Questionnaire [20], the Pittsburgh Sleep
Quality Index [21], and the Insomnia Severity Index
(ISI) [22]. In addition to these instruments, insomnia
symptom variables such as total sleep duration, sleep
latency, number of nighttime awakenings, and the affect
of prior night’s sleep on next-day-sleepiness are predo-
minant indicators of insomnia severity and are routinely
collected in clinical studies of insomnia [7].
Among the various instruments used for describing
insomnia, the ISI is one of the most commonly used
disease-specific measures for self-perceived insomnia
severity [23]. The ISI has 7 items describing insomnia-
related health impairments concerning 1) difficulty fall-
ing asleep; 2) difficulty staying asleep; 3) waking up too
early; 4) satisfaction with one’s current sleep pattern; 5)
self-perceived noticeability of current sleep problems to
others with regard to patient’s quality-of-life; 6) psycho-
logical burdens, and; 7) interference of sleep problems
with one’s daily functioning. Each item is rated on a 5-
point Likert scale with scores ranging from 0 to 4,
indicting “none”, “mild”, “moderate”, “severe” and “very
severe” sleep problems, respectively. The total ISI score
is calculated by summing the scores from the 7 items,
a n dr a n g ef r o mam i n i m u mo f0t oam a x i m u mo f2 8 ,
with higher scores reflecting more severe sleep pro-
blems. In clinical assessments, the ISI total summary
score falls into 1 of 4 ISI categories; with scores 0-7, 8-
14, 15-21, and 22-28 indicating no clinically significant
insomnia, sub-threshold insomnia, moderate insomnia
and, clinically severe insomnia, respectively. The psycho-
metric properties of the ISI have been evaluated in ear-
lier studies and have been reported to have sound
measurement quality for measuring perceived insomnia
severity and the impact of insomnia in different popula-
tions [22,24,25].
To quantify the impact of insomnia severity in eco-
nomic studies such as cost utility analyses (CUA), pre-
ference-based measures are required to capture patient
preferences for a particular health state [26]. Preference-
based measures can be used to generate health state uti-
lities based on a continuous scale whereby a utility of
1.00 represents “full” health and a utility score of 0.00
corresponds to “death”. Such anchored scores are neces-
sary to calculate quality-adjusted life-years (QALYs), a
measure of life adjusted for the quality of that life, so
that cross comparisons of different health care outcomes
are permitted in health economic evaluations [26-28].
Following guidance issued by the National Institute for
Health and Clinical Excellence (NICE, 2004) [29] in the
United Kingdom, preference-based measures such as the
EuroQol EQ-5D [30-32] or the Health Utility Indices
[33] have become common means of generating health
state utilities.
In particular, the EQ-5D is cognitively simple and
takes only a few minutes to complete without imposing
excessive response burden. It consists of five items
describing health in terms of mobility, self care, usual
activities, pain/discomfort, and anxiety/depression. Each
item has 3 levels whereby higher levels indicate greater
health deficits (1 = no problem, 2 = some problem and
3 = extreme problem). Hence, the EQ-5D descriptive
system defines a total of 243 (3
5) health states. Utility
values can be computed from EQ-5D item responses
using scoring algorithms [31,34]. Earlier studies have
used the EQ-5D in insomnia-related studies for different
populations, but mostly for secondary insomnia invol-
ving comorbid medical conditions such as depression or
cancer [35,36].
CUAs have recently been conducted in the field of
insomnia research [7,37-41]. Nonetheless, the evidence
regarding the relationship between objective and subjec-
tive sleep measures and quantifiable insomnia-related
health economic outcomes remains limited. In cases
where direct evidence elicited by preference-based mea-
sures is not available, establishing a mapping relation-
ship between descriptive clinical measures on insomnia
and quantitative effects of insomnia on HRQoL can be
useful.
T h ep u r p o s eo ft h ep r e s e n ts t u d yw a st h e r e f o r et o
establish such a mapping relationship between insom-
nia-related measures and the EQ-5D. We aimed to esti-
mate the associations between the EQ-5D health state
utilities and insomnia severity measures by mapping the
ISI and/or predominant indicators of insomnia onto the
EQ-5D.
Methods
Survey
The analysis was based on a cross-sectional internet sur-
vey of approximately 3,000 US residents with signs and
symptoms suggestive of chronic insomnia. This was an
observational study designed to explore the relationship
between subject-reported sleep measurements and out-
comes (i.e. quality of life, functionality, and impact of
sleep) in the US community. The survey was fielded by
Harris Interactive which maintains a proprietary web-
enabled panel of research subjects in the US who have
agreed to participate in ongoing survey research.
Prior to the screening of any potential subjects, a cen-
tral Institutional Review Board (IRB) approved the pro-
tocol (GHO-2008-008, 1/5/09), informed consent form,
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and/or recruitment materials. To recruit participants,
e-mail invitations were sent to approximately 90,000
panel members representative of the general public. It
was estimated that approximately 20% of the panel
members in the specified subset would respond to the
e-mail invitation. Of those, a 60% qualification rate
was assumed among those insomnia-diagnosed
patients. Overall, approximately 3,000 subjects were
expected to enroll and complete the study. The study
duration was estimated to be roughly 8 weeks, which
included time for subject recruitment and completion
of the questionnaire.
Data
Subjects completed a questionnaire that collected infor-
mation on demographics, comorbidities, and previous-
night sleep symptoms. Subjects also provided responses
to the ISI and the EQ-5D. Subjects with complete
responses on the EQ-5D and the ISI questionnaire were
included in the study if they a) were at least 18 years of
age; b) provided informed consent to participate in the
survey; c) were at least moderately bothered by their
sleep problems; d) had reported problems with (i) falling
asleep at the beginning of the night (ii) staying asleep
throughout the night or (iii) not feeling refreshed upon
waking following what was expected to be an adequate
night’s sleep for at least 3 times per week, or (iv) at least
2 of the problems listed above at least once per week.
Subjects were excluded from the study if they 1) were
employed in full-time or part-time jobs that involved
night shifts or day-night rotating shifts; 2) had children
under 1 year old; or 3) reported a physician-diagnosis of
competing symptoms of sleep such as obstructive sleep
apnea, narcolepsy, periodic limb movement disorder, or
restless leg syndrome.
Models and Variables
A series of generalized linear models (GLM) was used
for the present analysis. Based on the distribution of the
variables, we indentified a gamma family distribution
and a log link using the Modified Park tests for model
specifications [42,43]. The dependent variable was the
EQ-5D utilities computed based on the responses to the
5 items using a US algorithm [34]. While the gamma
family was selected to account for the skewed dependent
variable distribution, to respect its distribution for real
values on a positive space (from 0 to ∞) [43], the mod-
eled dependent variable was constructed as the disutility
values of the EQ-5D (= 1-utility) computed using the
following equation:
Utility =1− Disutility =1− exp(α +

Xiβ) (1)
Four GLM functional forms were used (Table 1). For
Models I-III the predictors for the EQ-5D disutility
values were the 7 ISI items, a continuous (0-28) ISI
summary score, and the 4 ISI clinical categories, respec-
tively. For Model IV, we used sleep symptom variables
identified from the existing literature on insomnia
[7,44-46], namely, previous night’s sleep duration, sleep
quality, sleep latency, next-day-sleepiness as an effect of
prior night’s sleep, and the number of wakeup times
during the night. Predictors in Model IV were supple-
mented with patient characteristics such as age, gender,
and the presence/absence of comorbidities.
The comorbidity predictor was constructed as a bin-
ary variable representing the presence (= 1) or absence
(= 0) of any of the 17 chronic non-insomnia-compet-
ing conditions reported by the respondents based on
prior physician diagnoses. The chronic conditions
included: anxiety disorder, arthritis, bipolar disorder,
cancer, cardiovascular condition, chronic fatigue syn-
drome, chronic pain, depression, diabetes, drug/alcohol
abuse, fibromyalgia, HIV/AIDS, insomnia, irritable
bowel syndrome, neuropathic pain, respiratory condi-
tion, and schizophrenia.
The decision to use a single binary(yes/no) comorbid-
ity presence indicator rather than one variable per con-
dition or counting the sum of the total number of
conditions was made, primarily, to impose a minimal
burden on future data collection. Specifically, it should
be emphasized that the objective of this study was not
to predict utility levels using a large number of clinical
and demographic variables. Rather, we sought to con-
struct a simple–if not generic–tool that would allow
researchers to predict utility in a community-based
population of individuals exhibiting insomnia symptoms
u s i n ga sf e wv a r i a b l e sa sp o s s i b l e .U l t i m a t e l y ,w eh o p e
that the algorithm generated in this process can be used
by researchers who either could not collect utilities in
previous research or, for other reasons, will not be able
to do so in the future. Hence, the focus of this analysis
was on external rather than internal validity. The
approach selected herein with regard to comorbidity
was consistent with the broader sleep-research literature
which emphasizes insomnia without comorbidities (i.e.,
primary insomnia) from insomnia with comorbidities (i.
e., secondary insomnia).
For the sleep duration variable used in the Model IV,
based on preliminary analysis of the predictors, observed
EQ-5D health state utility was found to be optimal when
the amount of sleep was approximately 7-9 hours (mean
[standard deviation, SD] sleep duration = 7.8 [1.9]
hours). EQ-5D utility decreased when one slept more/
less than that optimal amount or extreme hours, which
gave a concave sleep duration function of EQ-5D utility/
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variable was included in the model.
Moreover, the sleep quality-rating variable ranged
from 0, indicating poor sleep quality to 10, indicating
excellent sleep quality. The next-day-sleepiness item
also used a rating ranging from 0 suggesting not feeling
sleepy due to prior night’s sleep pattern to 10 for feeling
extremely sleepy. Sleep latency was captured using total
minutes of delay to sleep and the total number of wake
up times during the night ranged from minimum of 1
time to a maximum of 5 times. We treated these predic-
tors as continuous for simplicity.
Analyses
We used 50% of the sample to generate the mapping
function (i.e., estimation sample) and, the other 50% to
validate the model performance (i.e., validation sample).
Samples were randomly split for each process. Predic-
tions in the validation process were made based on
parameters estimated from estimation sample. The vali-
dation process was repeated 30 times to ensure we
obtained a sufficient number of predictions to account
for variability. Average values from the 30 validations
were calculated for each of the 4 models.
To determine the predictive precision of the models,
we computed model mean square error (MSE) and
mean absolute error (MAE). The MSE was given by:
MSE =

(Y − ˆ Y)
2
N − K
where Y = observed EQ-5D values,
ˆ Y = predicted EQ-5D values, N = total or subgroup
sample sizes and, K = degrees of freedom. Hence, the
MSEs were computed by adjusting the number of inde-
pendent variables included in the model. Thus, a perfect
prediction would be indicated by a zero MSE and, smal-
ler MSEs indicated lower prediction errors. Since MSEs
penalized larger errors by using the squared term of
errors, we also computed the MAE. The MAE was given
by: MAE =
 
Y − ˆ Y
 

N
,a g a i n ,Y=o b s e r v e dE Q - 5 D
values, ˆ Y = predicted EQ-5D values N = total or sub-
group sample sizes, The MAEs provided error statistics
that did not give greater weight to larger errors.
The overall model performance was also assessed by
examining the distributional qualities of the predicted
EQ-5D scores compared with the observed ones with
regard to mean, median, min/max, and range. SAS 9.2
was used for data preparation, STATA11 was used for
Table 1 Model overview
Dependent Variable (For Models
I-IV)
Independent Variables and Models
Model I: ISI 7 items
Utility mod elI =1− exp(α +
7 
j=0
Xiβij)Where
0 
j=0
Xiβi0 ≡ 0 and, i = 1,...,7 representing 7 ISI items,
j = 0,...,4, representing 5 levels of the Likert scale.
Model II: ISI summary scores (0-28)
UtilityModelII =1− exp(α + Xβ)Where X is the ISI summary scores range from 0(min) to 28
(max) and treated as a continuous variable in the model
EQ-5D disutility values
Disutility = exp(α +

Xβ)
Utility = 1-Disutility
Model III: ISI 4 clinical categories
UtilityModelIII =1− exp(α +
4 
j=1
Xβij)Where
1 
j=1
Xiβi1 ≡ 0and, j = 1,...,4 representing 4 clinical
classifications based on insomnia summary scores.
Model IV: Insomnia symptoms and demographics
UtilityModelIV =1− exp(α +
8 
i=1
Xiβi + X2
duration2βduration2)Where i = 1,...,8 representing 5
symptoms, 2 demographic variables and 1 variable indicating the presence/absence of comorbidity. The 5
symptom variables were: sleep duration, quality, latency, next day sleepiness, and number of wakeup times during
the night. The 2 demographic variables were age and gender. Within the model, a sleep duration squared term
was an additional predictor adjusting the concave function of sleep duration on health state utilities.
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used for prediction error computations.
Results
Of the 3,034 survey participants, 2,842 (93.67%) met all
inclusion/exclusion criteria and were included in the
present analyses. Table 2 reports respondents’ socio-
demographic characteristics. The mean (± SD) age of
the total sample was 42.9 (± 15.7) years. Nearly two
thirds of respondents were female and 83.7% were Cau-
casian. The mean (± SD) observed EQ-5D utility score
was 0.765 (± 0.20) and was lowest for individuals aged
50 to 59 (0.749 [± 0.20]). On average, respondents
reported 7.8 (± 1.9) hours of sleep during the previous
night. The mean (± SD) ISI summary score was 14.1 (±
4.8). According to the ISI clinical classification, 6.19%,
52.08%, 33.57%, and 8.16% of respondents were categor-
ized as having no clinically significant insomnia, sub-
threshold insomnia, moderately severe insomnia, and
severe insomnia, respectively. Individuals aged 40 to 59
reported the least mean (± SD) amount of sleep dura-
tion (7.5 [± 1.8]) and higher scores on ISI items, sug-
gesting greater sleep problems. In addition, compared
with male respondents, females reported longer mean
sleep durations (7.9 vs. 7.5 hours) and higher mean EQ-
5D scores (0.766 vs. 0.762) despite higher ISI summary
scores (14.3 vs. 13.7). In this particular sample 62.4% of
respondents reported ≥ 1 comorbid medical conditions
and, for those who reported ≥ 1 comorbid conditions,
mean EQ-5D scores were lower compared with those
who reported no comorbid conditions (0.723 vs. 0.835).
ISI summary scores decreased (i.e., insomnia improved)
as sleep quality improved, and increased (i.e., insomnia
worsened) with rating increases of next-day-sleepiness,
sleep latency, and number of wake-up times. Therefore,
a longer time to fall asleep and a greater number of
wake-up times during a night were associated with
higher ISI scores and lower the EQ-5D utility values.
Table 3 exhibits the model regression estimates using
the different set of predictors on EQ-5D disutility. For
Model I, except for ISI item 4 (i.e., degree of satisfaction
with sleep pattern) and item 7 (extent of interference
with daily functioning due to sleep pattern), ISI items
showed significant associations with EQ-5D scores (p <
0.05). Higher levels of ISI items were associated with
greater health deficit (greater disutility values). ISI sum-
mary scores in Model II and clinical classification scores
in Model III also showed significant associations with
EQ-5D disutility values (p < 0.001). In Model IV, except
for age and gender, all other predictors were able to
provide substantial explanations of EQ-5D scores (p <
0.05). The signs of model coefficients were as expected.
Table 4 compares the mean, median, min/max, and
range of observed and predicted EQ-5D values for both
estimation and validation sample estimates. EQ-5D uti-
lity values were computed using equation (1). The
observed EQ-5D mean (± SD) utility value was 0.765 (±
0.18), with a median value of 0.800 and a range of
[-0.040-1.000]. Mean predicted scores were identical
with those observed for three ISI models (Models I-III).
The predicted mean was slightly higher for Model IV,
when insomnia symptoms were used for prediction
(0.771 (± 0.07)), compared with Models I-III using ISI
(0.765 (± 0.08)). Similar results were found in validation
sample estimates.
Table 5 shows the model prediction errors. The MSEs
and MAEs were lower for EQ-5D utilities greater than
0.40. This suggested that predictions were more robust
for higher health state utilities (i.e., > 0.4), which were
reported by 94.02% of the respondents in the sample. At
the same time, relatively poorer predictions at tail end
of utilities have been reported as a common problem
associated with mapping [47]. Owing to the very small
sample size (0.63%) of respondents who had observed
utilities < 0.2, MSEs for EQ-5D utilities less than 0.2
could not be computed in Models I and IV. Similar
results were found using the validation samples.
Figure 1 depicts observed and predicted EQ-5D utility
v a l u e sf o rM o d e l sI - I Va l o n gt h eI S Is c o r e s( r a n g i n g
from 0 to 28), which showed negative correlations
between the two instruments. The predicted EQ-5D uti-
lity values followed more closely with observed ones for
mid-range scores, especially for Models I-III. For Model
IV, EQ-5D utility values were under-predicted for ISI
scores less than 14 (no insomnia or threshold insomnia)
and over-predicted for ISI scores greater than 14 (mod-
erate or severe insomnia). Nevertheless, the association
between greater insomnia symptom severity and lower
health utilities was observed in all models.
Figure 2 shows the observed and predicted EQ-5D
values along sleep duration using half-hour intervals.
Again, predicted and observed EQ-5D utilities followed
each other closely along sleep durations except for the
higher and lower ends of sleep hours (i.e., extreme
hours). The concave function of sleep duration of the
EQ-5D utility was preserved, suggesting that health state
utilities increase at a decreasing rate along sleep
durations.
Discussion
The extent of association between a disease-specific
instrument (i.e., ISI) and a generic preference-based
instrument (i.e., EQ-5D) is affected by the amount of
correspondence between the two measures with regard
to the underlying HRQoL [48]. Findings from this analy-
sis suggest there was sufficient overlapping of underlying
HRQoL between insomnia measures and EQ-5D health
state utilities. While the ISI is commonly used in clinical
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Number % Mean Age (SD) (Years) Mean (SD)
EQ-5D
Mean Duration (SD) (Hours) Mean ISI
(SD)
Whole sample 2,842 100 42.9 (15.7) 0.765 (0.2) 7.8 (1.9) 14.1 (4.8)
Age group
18-29 743 26.1 24.2 (3.8) 0.784 (0.2) 8.0 (1.9) 13.4 (4.6)
30-39 569 20.0 34.7 (2.9) 0.754 (0.2) 7.7 (1.9) 15.0 (5.0)
40-49 624 22.0 45.0 (2.8) 0.754 (0.2) 7.5 (1.8) 15.0 (4.7)
50-59 405 14.3 54.9 (2.8) 0.749 (0.2) 7.5 (1.8) 14.2 (4.7)
60-69 351 12.4 64.2 (2.9) 0.770 (0.2) 7.9 (1.9) 12.9 (4.5)
≥ 70 150 5.30 74.8 (4.6) 0.786 (0.1) 8.1 (1.6) 12.3 (4.7)
Gender
Female 1,834 64.50 42.0 (15.9) 0.766 (0.2) 7.9 (1.9) 14.3 (4.8)
Male 1,008 35.50 44.5 (15.2) 0.762 (0.2) 7.5 (1.8) 13.7 (4.7)
Race
White 2,318 83.7 44.0 (15.7) 0.768 (0.2) 7.8 (1.8) 13.9 (4.7)
Black 292 10.5 38.1 (14.7) 0.755 (0.2) 7.4 (2.1) 14.7 (5.1)
Asian 44 1.60 26.7 (10.4) 0.805 (0.1) 7.4 (2.1) 13.7 (3.7)
Other 116 4.20 38.3 (13.7) 0.719 (0.2) 7.5 (2.1) 15.7 (5.3)
Comorbidity
No 1068 37.60 38.2 (14.4) 0.835 (0.1) 7.7 (1.8) 12.7 (4.3)
Yes 1774 62.40 45.7 (15.8) 0.723 (0.2) 7.8 (1.9) 14.9 (4.9)
Sleep quality
0 146 5.14 43.6 (13.4) 0.614 (0.2) 6.6 (2.5) 20.5 (5.1)
1 94 3.31 43.7 (15.7) 0.697 (0.2) 7.2 (2.3) 18.3 (4.8)
2 250 8.81 43.9 (14.2) 0.712 (0.2) 7.4 (2.2) 17.1 (4.6)
3 457 16.10 44.0 (15.0) 0.755 (0.2) 7.7 (1.9) 15.5 (4.1)
4 457 16.10 41.6 (14.8) 0.763 (0.2) 7.9 (1.8) 13.9 (4.0)
5 559 19.70 43.3 (15.7) 0.795 (0.1) 7.8 (1.6) 12.9 (3.9)
6 411 14.48 40.9 (16.8) 0.800 (0.1) 8.0 (1.6) 12.2 (3.7)
7 291 10.25 42.7 (17.0) 0.804 (0.2) 8.0 (1.7) 11.6 (4.1)
8 108 3.81 43.8 (17.8) 0.781 (0.2) 8.4 (1.8) 10.9 (4.0)
9 35 1.23 40.5 (18.3) 0.858 (0.2) 8.5 (1.2) 11.7 (5.2)
10 30 1.06 48.3 (17.6) 0.727 (0.3) 8.0 (2.2) 10.5 (5.7)
Next day sleepiness
0 162 5.71 54.0 (15.8) 0.764 (0.2) 7.8 (2.0) 12.4 (5.4)
1 100 3.52 49.3 (16.6) 0.805 (0.2) 8.0 (2.0) 12.2 (4.5)
2 157 5.53 45.0 (16.9) 0.792 (0.2) 7.9 (1.8) 12.5 (4.0)
3 213 7.51 46.0 (16.0) 0.788 (0.2) 7.8 (1.7) 12.4 (4.1)
4 236 8.32 44.6 (16.1) 0.776 (0.2) 7.8 (1.8) 13.0 (4.1)
5 373 13.15 44.4 (15.6) 0.781 (0.2) 7.9 (1.8) 13.5 (4.3)
6 436 15.37 40.9 (15.4) 0.783 (0.2) 7.8 (1.9) 13.5 (4.2)
7 520 18.33 40.6 (14.2) 0.758 (0.2) 7.8 (1.8) 14.7 (4.6)
8 364 12.83 38.4 (14.3) 0.747 (0.2) 7.7 (1.9) 15.6 (4.8)
9 135 4.76 40.5 (13.7) 0.683 (0.2) 7.5 (2.1) 16.2 (5.3)
10 141 4.97 39.2 (14.0) 0.710 (0.2) 7.2 (2.2) 18.1 (5.5)
Latency (minutes)
< 15 443 17.39 44.2 (15.2) 0.808 (0.1) 7.7 (1.7) 11.9 (4.3)
15-30 468 18.37 44.7 (16.5) 0.799 (0.2) 7.8 (1.7) 12.3 (4.1)
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uate insomnia severity, it does not provide the prefer-
ence-based measures necessary for health economic
evaluations quantifying the impact of insomnia on
patients’ health state utilities. To the best of our knowl-
edge, the present study is the first to map an insomnia-
specific instrument and/or sleep variables to EQ-5D uti-
lity values. Hence, the cross-walk conducted herein
establishes a preliminary mapping relationship and link
between these measures.
Findings from this analysis were consistent with earlier
studies wherein poorer sleep outcomes (e.g., sleep qual-
ity, next-day-sleepiness, and extreme sleep hours) were
significantly associated with declining HRQoL [8,12,49].
Such associations were observed in the present analysis,
especially for individuals with greater sleep difficulties
(Figure 1) or extreme sleep durations (Figure 2).
With respect to sleep duration for example, a recent
study by Faubel et al. (2009) reported that for older
men and women, extreme sleep durations (≤ 5h o u r so r
≥ 10 hours) were indicators of worse HRQoL, compared
with those who sleep 7-8 hours per night [8]. Studies of
different populations have also reported this same effect:
that short-duration sleep [50] or long-duration sleep
[51] or both [52], were associated with worse HRQoL.
This association was noted in our model predictions by
taking other factors into consideration (Model IV).
Quantifying the effect of insomnia on HRQoL is
essential for targeting effective treatments, and com-
paring treatment cohorts in clinical practice. The map-
ping relationship established between the ISI and the
E Q - 5 Di nt h i sa n a l y s i sp r o v i des a necessary cross-walk
when a preference-based measure such as EQ-5D was
not administered. For example, using a hypothetical
scenario where a 36-year old female had ISI item
scores of 0, 3, 1, 4, 3, 3, and 2, which would result in
a nI S Is u m m a r ys c o r eo f1 6a n daI S Ic l a s so f3 .
Further, she also reported 8.58 hours of sleep, ≥ 1
comorbidity, 1 on overall sleep quality, 5 minutes of
sleep onset latency during previous night, 8 on next
day sleepiness, and 5 wake-up times. Using the algo-
rithms provided (Table 1 equation (1)), her estimated
EQ-5D utility values would be 0.772, 0.748, 0.723, and
0.690 using Models I-IV, respectively (see Table 6 for
sample computations).
For this particular scenario, compared with Model I,
the estimated utilities using Models II and III were
decreased by approximately 3% and 6%, respectively
(0.772 vs. 0.748 and 0.723). When Model IV was used,
the estimated utility was lower by 10% (0.772 vs. 0.690).
These discrepancies were associated with different
model specifications as each model incorporated differ-
ent assumptions. In Model I, the predictions based on 7
distinctive item scores were able to capture more precise
information for describing the EQ-5D and different
items categories were assumed to have their own weight
on the EQ-5D scores. Conversely, in Model II a contin-
uous summary score ranging from 0 to 28 was used.
This assumed that each unit increment/decrement in
total ISI score would give the same impact on the EQ-
5D regardless of which item. The case is similar for
Model III, where the clinical categories were constructed
based on the summary scores. One way to conceptualize
this is to understand that Models II and III penalized
the estimated utilities by placing more weight on the
items that had more impact on the EQ-5D. Model IV is
a different model specification aimed to estimate the
same outcome. It captured mored i s e a s e - s p e c i f i ci n f o r -
mation in explanatory variables, and therefore the esti-
mated EQ-5D utilities were penalized the most.
Alternatively, these discrepancies could be lowered by
using a sample scenario with all best levels of ISI items
where no problems were reported on all items, i.e.,
score = 0 on all items. Using the same computation, the
estimated utilities for Models I-III would be approxi-
mately 0.914, 0.905 and 0.868, respectively, resulting 1%
and 5% differences in estimated utilities using Models II
and III, respectively compared with Model I. Given
these findings, Model I should be used when data for all
ISI items are available.
Table 2 Sample Characteristics (Continued)
30-45 449 17.62 42.9 (16.0) 0.791 (0.1) 7.8 (1.7) 13.5 (4.3)
45-60 205 8.05 41.8 (15.0) 0.773 (0.2) 7.6 (1.7) 13.9 (4.3)
60-90 404 15.86 42.3 (15.1) 0.752 (0.2) 7.8 (1.8) 14.6 (4.4)
> = 90 579 22.72 40.5 (15.9) 0.729 (0.2) 8.0 (2.1) 15.9 (4.7)
Wake up times
1 375 18.20 43.6 (15.4) 0.802 (0.2) 7.5 (1.7) 12.8 (4.3)
2 732 35.6 44.5 (16.1) 0.780 (0.2) 7.7 (1.7) 13.6 (4.5)
3 588 28.6 44.1 (15.6) 0.759 (0.2) 8.0 (1.8) 14.3 (4.4)
4 184 8.90 44.9 (15.2) 0.743 (0.2) 8.3 (1.8) 15.6 (4.7)
5 179 8.70 42.6 (13.0) 0.715 (0.2) 8.4 (1.8) 16.2 (4.6)
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Page 7 of 13Table 3 Model Estimations
Model I Model II Model III Model IV
Intercept -2.45614 (0.27103) **** -2.34909 (0.0493) **** -2.0259 (0.0733) **** -0.99338 (0.17896) ****
ISI_1
1 0.04681 (0.05083) –––
2 0.14743 (0.04637) *** –––
3 0.23814 (0.05315) **** –––
4 0.20228 (0.08007) ** –––
ISI_2
1 -0.00487 (0.06257) –––
2 0.10069 (0.05168) * –––
3 0.1438 (0.0581) ** –––
4 0.22504 (0.08002) *** –––
ISI_3
1 -0.04075 (0.04682) –––
2 0.00373 (0.04365) –––
3 0.13501 (0.05178) *** –––
4 0.15058 (0.06278) ** –––
ISI_4
1 0.30681 (0.28409) –––
2 0.23039 (0.26934) –––
3 0.14912 (0.26789) –––
4 0.13552 (0.26478) –––
ISI_5
1 0.18721 (0.12667) –––
2 0.3242 (0.12139) *** –––
3 0.41963 (0.12265) *** –––
4 0.58239 (0.12811) **** –––
ISI_6
1 0.13325 (0.0471) *** –––
2 0.16124 (0.04784) *** –––
3 0.24329 (0.05675) **** –––
4 0.38139 (0.06977) **** –––
ISI_7
1 0.04661 (0.07847) –––
2 0.0766 (0.07898) –––
3 0.11301 (0.0838) –––
4 0.16077 (0.09968) –––
ISI summary – 0.06077 (0.00307) **** ––
ISI class
2 –– 0.36953 (0.07558) **** –
3 –– 0.74122 (0.07544) **** –
4 –– 1.15809 (0.08459) **** –
Age ––– -0.00079 (0.00103)
Female ––– -0.03204 (0.02736)
Duration ––– -0.22818 (0.04158) ****
Duration
2 ––– 0.0133 (0.00265) ****
Comorbidity ––– 0.42901 (0.02861) ****
Sleep quality ––– -0.0314 (0.00953) ***
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Page 8 of 13Based on the findings, marginal changes on treatment
effects on insomnia could also be estimated. If the same
respondent had improved her sleep pattern somehow
and decreased her ISI score to 14 (from 16), then by
using Model II, her predicted EQ-5D utility score would
be 0.776 (= 1-exp(-2.34909+ 0.06077* 14) instead of
0.748, corresponding to a difference of approximately
0.0289 unit of utility. On the other hand, holding other
variables constant and assuming changes to ISI item 5
(e.g., if she thought her sleep problem was noticed “a lit-
tle by others” (level 1)); then using the Model I algo-
rithm, her health utility would be 0.761 (= 1-exp
(-2.45614+0.04681+0.14380-0.04075+0.13552+0.41963
+0.24329+0.0766)), instead of 0.772. Similar magnitudes
of health disutility gains and losses could be estimated if
changes had taken place on other ISI items. From a
health policy standpoint, such quantification is useful
for assessing the effect of treatment on health utility
values. Thus, the findings provided herein make it possi-
ble to estimate EQ-5D utility values when direct evi-
dence is absent from the primary research, but when ISI
or insomnia-related symptoms data are available.
It is important to note the limitations of this study.
First, while significant associations were noted between
insomnia measures and EQ-5D utilities in the current
study, the mapping technique implicitly assumes that
the EQ-5D covers all important aspects of the latent
health construct that the ISI is intended to measure.
Hence, the strength of the mapping function is under-
pinned by the degree of overlap between the two
measures. While all model estimates rendered very close
approximations of the EQ-5D observed scores, the
regression-based transformation presented herein is self-
contained in that disease-specific scores are permitted
to be transformed to a generic utility measure without
referencing additional data and aimed for repeated uses
on secondary data analysis from other clinical trials [48].
Therefore, the external validity of the study should be
verified using other data sets.
Second, since different models control for different
predictors, each entails a different magnitude of effects.
At the group level, predicted mean utility values closely
estimated observed values. At the individual level, algo-
rithms presented in this study may include some discre-
pancies from one model to another, as was indicated in
the above example. Therefore, our algorithms may more
accurately predict individual EQ-5D values for a group
level evaluation for CUA studies in making group level
comparisons.
Third, regression-based mapping from one measure to
another inevitably results in floor and ceiling effects for
predicted values [48]. We noted higher MSEs in all
models for lower EQ-5D utility values (EQ-5D < 0.4)
Thus, our algorithms were less reliable for respondents
with EQ-5D scores < 0.4.
Fourth, QALYs implicitly involve the concept of survi-
val, but we estimated health utility values with a cross-
sectional data set. Hence, the directional effects of
insomnia on patients’ utility over time, or, the respon-
siveness of the estimates could not be assessed in the
Table 3 Model Estimations (Continued)
Latency ––– 0.00112 (0.00026) ****
Sleepiness ––– 0.02498 (0.00754) ***
Wake times ––– 0.05213 (0.01348) ****
Log-likelihood 1378.765 1405.107 1392.894 1018.948
For model specifications please refer to Table 1
ISI class_1 = No clinically significant insomnia; ISI class_2 = Subthreshold insomnia; ISI class_3 = Moderate insomnia; ISI class_4 = Se were insomnia
* p < 0.10; ** p < 0.05; *** p < 0.01; **** p < 0.001
Table 4 Comparison of observed and predicted EQ-5D utility values
Mean (SD) Median [Min-Max] Range
Observed 0.765 (0.18) 0.800 [-0.040-1.000] 1.040
Estimation Sample Model I 0.765 (0.08) 0.783 [0.407-0.914] 0.507
Model II 0.765 (0.07) 0.776 [0.477-0.905] 0.428
Model III 0.765 (0.07) 0.809 [0.580-0.868] 0.288
Model IV 0.771 (0.07) 0.772 [0.324-0.895] 0.571
Validation Sample Model I 0.766 (0.08) 0.786 [0.367-0.891] 0.524
Model II 0.765 (0.07) 0.776 [0.488-0.896] 0.408
Model III 0.764 (0.07) 0.811 [0.571-0.858] 0.287
Model IV 0.774 (0.07) 0.777 [0.321-0.906] 0.585
For model specifications please refer to Table 1
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Page 9 of 13Table 5 Assessing model predictions
N Model I Model II Model III Model IV
MSE MAE MSE MAE MSE MAE MSE MAE
Estimation Sample Full index 1421 (100%) 0.024 0.109 0.025 0.110 0.026 0.112 0.024 0.110
< 0.2 10 (0.68%) N/A 0.545 0.375 0.566 0.424 0.567 N/A 0.526
0.2-0.4 53 (3.76%) 0.184 0.350 0.146 0.366 0.155 0.377 0.192 0.392
0.4-0.6 164 (11.57%) 0.070 0.232 0.066 0.235 0.068 0.241 0.072 0.250
0.6-0.8 329 (23.15%) 0.008 0.066 0.007 0.063 0.007 0.064 0.005 0.057
0.8-1.0 865 (60.85%) 0.013 0.083 0.013 0.084 0.014 0.085 0.013 0.087
Validation Sample Full index 1421 (100%) 0.025 0.110 0.024 0.110 0.025 0.111 0.023 0.108
< 0.2 10 (0.73%) N/A 0.538 0.351 0.555 0.389 0.547 N/A 0.502
0.2-0.4 53 (3.70%) 0.209 0.373 0.157 0.381 0.165 0.388 0.207 0.407
0.4-0.6 163 (11.44%) 0.071 0.233 0.064 0.234 0.067 0.235 0.071 0.246
0.6-0.8 326 (22.95%) 0.008 0.069 0.007 0.061 0.007 0.064 0.006 0.061
0.8-1.0 869 (61.18%) 0.013 0.083 0.013 0.084 0.014 0.085 0.013 0.087
-MSE = Mean square error.
-N/A = Estimates were not available due to the small sample size
-MAE = Mean absolute error
- Note: For model specifications please refer to Table 1
-Sample size for both the estimation and validation sample was randomly drawn (50%) from the total qualified participants (N = 2,842).
Figure 1 Observed and predicted EQ-5D utility values along ISI scores. Note: For model specifications please refer to Table 1.
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Page 10 of 13present study. It is therefore unclear whether the mathe-
matical links reported in this study would vary over
time.
Fifth, the current study relied on respondents’ self-
reported health status and not on physician assessment or
medical records. Hence, the aim was not to identify cause-
and-effect relationships between sleep problems and other
specific conditions or parameters. Interestingly, findings
based on responses from such a convenient sample and
not from a controlled clinical study were strikingly consis-
tent with the study hypotheses, which provided vital valid-
ity of the analyses.
Sixth, treating the sleep quality variable in Model IV
as continuous was a simplistic approach which assumed
that each unit increase in sleep quality equally impacted
the EQ-5D. Comparisons on the prediction results using
the continuous and the categorical sleep quality showed
that both approaches had equivalent predicted
Figure 2 Observed and predicted EQ-5D utility values along sleep duration (in half-hour intervals). Note: For model specifications please
refer to Table 1.
Table 6 Sample utility computation
Model EQ-5D utility Computation
I 0.772 ≈1-exp(-2.45614+0+0.14380-0.04075+0.13552+0.41963+0.24329+0.0766)
II 0.748 ≈1-exp(-2.34909+ 0.06077*16)
III 0.723 ≈1-exp(-2.0259+ 0.74122)
IV 0.690 ≈1-exp(-0.99338-0.00079*36-0.03204*1-0.22818*8.58+0.0133*8.58
2+0.42901*1-0.0314*1+0.00112*5+0.02498*8+0.05213*5)
Sample scenario:
Assume a 36-year old female had ISI scores of 0, 3, 1, 4, 3, 3, and 2 on the 7 items, respectively, resulting in an ISI summary score of 16 and a ISI class of 3, in
combination with a report of 8.58 hours of sleep, ≥ 1 comorbidity, 1 on overall sleep quality, 5 minutes of sleep onset latency during previous night, 8 on next
day sleepiness, and 5 wake up times.
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Page 11 of 13outcomes; although, the trade-off was that distinctive
effects on each sleep quality categories on the EQ-5D
could not be separated under the continuous approach.
Since the purpose of this study was to obtain the best
estimates of the EQ-5D based on pre-defined predictors,
we reported our findings under the continuous
approach in Model IV.
Finally, the binary indicator of comorbidity used
herein disregarded the possibility that a respondent with
more than one comorbidity would likely report a worse
utility, all other things being equal, than a respondent
with one comorbidity. Likewise, this approach did not
take into account which comorbidity was present, thus
ignoring the possibility that some condition may have
had a stronger impact on utility than others. It was
beyond the scope of the present analysis to capture a
more detailed quantification of these effects. Rather, an
approximation of the EQ-5D utility values based on
included parameters could be implemented using Model
IV. Based on our findings, such approximation or esti-
mation could be carried out in patients with either no
comorbidities (i.e., primary insomnia) or in patients with
one or more comorbidities (i.e., secondary insomnia).
More importantly, the model was implementable regard-
less of whether the comorbidity conditions were listed in
the current survey.
Conclusion
Estimating EQ-5D health state utility values using the
algorithms presented herein permits comparisons of
health outcomes in the absence of preference-based
measures. Despite the aforementioned limitations, these
algorithms give flexibility of computing EQ-5D health
state utilities using different types of empirical insomnia
data. Meanwhile the mapping relationship explored in
t h i ss t u d ys e r v e sa sa“second-best” approach relative to
direct elicitation of preference-based measures in clinical
studies. Out-of-sample validation of these algorithms is
encouraged to further establish the relationship between
insomnia measures and the EQ-5D. This is especially
true among patient groups with relatively lower
observed health state utility values.
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